identification or classification of such specimens. * * *"

Authority: Section 122 of the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554).

(Catalog of Federal Domestic Assistance Program No. 93.779, Medical Assistance Program; No. 93.773, Medicare—Hospital Insurance Program; and No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: September 15, 2004.

Mark B. McClellan,

Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 04–27527 Filed 12–14–04; 8:45 am] BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Statement of Organization, Functions and Delegations of Authority

This notice amends Part K of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Administration for Children and Families (ACF), as follows: Chapter KA, Office of the Assistant Secretary for Children and Families (OAS) as last amended October 16, 2001 (66 FR 52627) and Chapter KN, Office of Public Affairs (OPA) as last amended January 2, 1998 (63 FR 81-87). This notice announces the transfer of the Freedom of Information Act (FOIA) functions from the Office of the Executive Secretariat and places them in the Division of Public Information, Office of Public Affairs.

These Chapters are amended as follows:

I. Chapter KA, Office of the Assistant Secretary for Children and Families

A. Delete KA.20 Functions, Paragraph C in its entirety and replace with the following:

C. The Executive Secretariat (ExecSec) ensures that issues requiring the attention of the Assistant Secretary, Deputy Assistant Secretaries and/or executive staff are addressed on a timely and coordinated basis and facilitates decisions on matters requiring immediate action including White House, Congressional and Secretarial assignments. ExecSec serves as the ACF liaison with the HHS Executive Secretariat. It receives, assesses and controls incoming correspondence and assignments to the appropriate ACF component(s) for response and action and provides assistance and advice to ACF staff on the development of responses to correspondence. ExecSec provides assistance to ACF staff on the use of the controlled correspondence system. ExecSec coordinates and/or prepares congressional correspondence, tracks development of periodic reports and facilitates Departmental clearances.

II. Chapter KN, Office of Public Affairs

A. Delete KN.00. Mission in its entirety and replace with the following:

KN.00 Mission. The Office of Public Affairs (OPA) develops, directs and coordinates public affairs and communications services for ACF. OPA serves as liaison with the Office of the Secretary, Office of Public Affairs in processing the Freedom of Information Act inquiries for ACF and coordinates hot line calls received by the Office of Inspector General and the Government Accountability Office relating to ACF operations and personnel. OPA provides leadership, direction and oversight in promoting ACF's public affairs policies, programs and initiatives. OPA also provides printing and distribution services for ACF.

B. Delete KN.20 Functions paragraph B, in its entirety and replace with the following:

B. The Division of Public Information (the Division) develops and implements public affairs strategies to achieve ACF program objectives in coordination with other ACF components. The Division coordinates news media relations strategy; responds to all media inquiries concerning ACF programs and related issues; develops fact sheets, news releases, feature articles for magazines and other publications on ACF programs and initiatives; and manages preparation and clearance of speeches and official statements on ACF programs. The Division coordinates regional public affairs policies and public affairs activities pertaining to ACF programs and initiatives. The Division Director serves as liaison to the Office of the Secretary, Office of Public Affairs in processing the Freedom of Information Act inquiries and coordinates hot line calls received by the Office of Inspector General and the Government Accountability Office relating to ACF operations and personnel.

Dated: December 14, 2004.

Wade F. Horn,

Assistant Secretary for Children and Families. [FR Doc. 04–28052 Filed 12–22–04; 8:45 am] BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS. **ACTION:** Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Non-Small Cell Lung Cancer Cell Line H3255

Herbert K. Oie et al. (NCI)

DHHS Reference No. E–028–2005/0– Research Tool

Licensing Contact: Mojdeh Bahar; 301/ 435–2950; baharm@mail.nih.gov.

This invention, the H3255 cell line, was initiated from malignant cells isolated from the pleural effusion from a non-smoker Caucasian female. The cultured tumor cells, identified as Non-Small Cell Lung Carcinoma Cells (NSCLC), were found to have a mutation within the EGFR gene that made them very sensitive to certain growth inhibiting drugs, such as gefitinib (iressa). Cell lines sensitive to growth inhibitors could be used in the treatment of cancer as potential chemotherapeutic agents.

LRATlerin, Related Compounds and Methods of Use

Denise P. Simmons (NCI)

- U.S. Provisional Application No. 60/ 613,256 filed 27 Sep 2004 (DHHS
- Reference No. E–349–2004/0–US–01) Licensing Contact: Mojdeh Bahar; 301/ 435–2950; baharm@mail.nih.gov.
- The invention discloses combinations of anti-tumor agents and anti-